Status:
WITHDRAWN
Topical Timolol for the Treatment of Benign Vascular Periocular Lesions
Lead Sponsor:
Loyola University
Conditions:
Benign Vascular Periocular Lesions
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this research is to find out if the use of topical timolol 0.5% solution applied twice daily will help to shrink rosacea lesions around the eye.
Detailed Description
Benign vascular tumors of the eyelid are common causes of ocular morbidity. Capillary hemangiomas in children cause refractive and occlusive amblyopia. In adults, Rosacea-associated eyelid telangiecta...
Eligibility Criteria
Inclusion
- Presence of a benign vascular periocular lesion
Exclusion
- Allergy to timolol or beta-blocker class of drugs
- Lesion characteristics concerning for atypia or malignancy including madarosis, ulceration, and recurrence after previous surgery.
- Intraocular Pressure less than 10 mm Hg
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01250457
Start Date
June 1 2010
End Date
July 1 2012
Last Update
October 30 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Loyola University Medical Center
Maywood, Illinois, United States, 60153